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of type 1 diabetes has been suggested. Our aim was to retrospectively evaluate the association of
fasting plasma C-peptide values with micro- and macrovascular complications.
RESEARCH DESIGN AND METHODS — We recruited a clinic-based cohort of 471
type 1 diabetic patients born after 1945 and cared for in the period 1994–2004. Centralized
measurementsandstandardizedproceduresofascertainmentofmicro-andmacrovascularcom-
plications were employed. Individual cumulative averages of A1C up to 2007 were calculated.
RESULTS — Residual -cell secretion was detected even many years after diabetes diagnosis.
In multivariate linear regression analysis, fasting plasma C-peptide values were positively asso-
ciated with age at diagnosis (0.02; P  0.0001) and triglycerides (0.20; P  0.05) and
inverselyassociatedwithdiabetesduration(0.03;P0.0001)andHDLcholesterol(
0.006;P0.03).Theﬁnalmodelexplained21%offastingC-peptidevariability.Withrespect
to fasting C-peptide values in the lowest tertile (0.06 nmol/l), higher values were associated
with lower prevalence of microvascular complications (odds ratio [OR] 0.59 [95% CI 0.37–
0.94]) independently of age, sex, diabetes duration, individual cumulative A1C average during
the study period, hypertension, and cardiovascular diseases. No association was evident with
macrovascular complications (0.77 [0.38–1.58]).
CONCLUSIONS — Our study shows an independent protective effect of residual -cell
function on the development of microvascular complications in type 1 diabetes, suggesting the
potentialbeneﬁcialeffectoftreatmentthatallowsthepreservationofevenmodest-cellfunction
over time.
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T
ype 1 diabetes is due to chronic au-
toimmune destruction of insulin-
producing -cells. Few studies,
however,haveassessedchangesininsulin
secretion over time in affected people and
its relationship with diabetes complica-
tions (1–4). C-peptide has been widely
acceptedasthemostappropriatemeasure
of residual -cell function because it is
secreted on a basis equimolar to insulin
and, unlike the latter, is not removed in
the ﬁrst pass through the liver (5).
Studies have pointed out relation-
ships of residual -cell function with age
at diagnosis (6,7), markers of -cell auto-
immunity (8,9), and glycemic control
(10). The Diabetes Control and Compli-
cations Trial (4) has pointed out the ben-
eﬁts of higher and sustained levels of
C-peptide secretion; indeed, in the inten-
sivelytreatedgroup,evenmodestresidual
-cell secretion was associated with de-
creased incidence of microvascular com-
plications and hypoglycemia (4). The
next frontier for treating diabetes is now
consideredtobethepreservationof-cell
function by reducing the autoimmune
stimulus directed at pancreatic islets (11–
14). However, at present, it has been sug-
gested that a potential beneﬁcial effect on
micro- and macrovascular complications
might be achieved by administering C-
peptide in type 1 diabetic patients, al-
though clinical evidence is still quite
limited(15–17).Experimentalstudiesare
consistent regarding the biological effect
of C-peptide on Na
/K
-ATPase, endo-
thelial nitric oxide (NO) synthase activi-
ties, and nuclear factor-B activation of
endothelial cells that under high-glucose
conditions are subject to progressive dys-
function (15,18–19). The aims of this
study were to describe residual -cell se-
cretion of C-peptide and its effect on mi-
cro- and macrovascular complications, in
particular, independent of glycemic con-
trol and other risk factors.
RESEARCH DESIGN AND
METHODS— Out of a large clinic-
based cohort of 1,024 type 1 diabetic pa-
tients cared for at the academic diabetes
clinic at S. Giovanni Battista Hospital in
Turin, Italy, we recruited all born in or
after 1945 who had been examined at least
once during the period 1994–2004 (n 
573). A diagnosis of type 1 diabetes was
based on permanent insulin treatment
within 6 months of the initial diagnosis.
The patients at S. Giovanni Battista
Hospital are generally cared for three or
fourtimesperyearbydiabetologists,with
centralized measurements, updated clin-
ical information, and annual assessments
of complications according to standard-
ized procedures. For all patients, data re-
garding the presence of micro- and
macrovascular complications at the last
clinical assessment were retrieved from
clinicalrecordsupto2007,aswellasdata
concerning BMI, blood pressure, and
plasma values of fasting glucose, lipids,
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as either blood pressure 140/90 mmHg
or current antihypertensive treatment.
Cardiovascular disease was deﬁned as
physician-diagnosed myocardial infarc-
tion, angina, coronary artery bypass graft,
stroke,orarterialdiseaseoflowerlimbsor
epiaortic arterial trunks. Screening for di-
abetic nephropathy was performed mea-
suring the albumin-to-creatinine ratio
from the ﬁrst morning urine collection
and conﬁrming abnormal results with al-
bumin excretion rate from overnight
urine collection. Screening for diabetic
retinopathy was performed locally by
trained diabetologists and ophthalmolo-
gists, who also performed laser therapy
when indicated. Distal symmetrical poly-
neuropathy was diagnosed on the basis of
presence of one or more neuropathic
symptoms, absence of two or more ankle
or knee reﬂexes, and abnormal vibration
perception threshold, measured by bio-
thesiometers on the right big toe and on
the right medial malleolus. Autonomic
neuropathy was deﬁned as a loss of heart
ratevariabilitywithanR-Rratio1.04or
posturalhypotensionwithafallinsystolic
blood pressure 20 mmHg. Residual
-cell function was assessed at the initial
visit at the clinics in prevalent cases or at
disease stabilization in incident cases, by
measuringfastingplasmaC-peptide(nor-
malvalues0.36–1.17nmol/l;Diagnostics
Product Corporation, Los Angeles, CA).
Of the 573 individuals of the study base,
plasmaC-peptidevalueswereavailablein
471 (82.2%). The median lag time be-
tween C-peptide measurement and last
clinical assessment of complications was
4.5 years (interquartile range 2.1–6.8).
Cumulative individual averages of
A1C over the observational study period
(1994–2007)werecalculated.Markersof
-cell autoimmunity (GAD antibodies
[GADAs] and islet cell antibodies [ICAs])
were assessed at the same time as C-
peptide plasma levels. GADAs were mea-
suredbyaradioligandassayusinghuman
recombinant GAD65 as the antigen (Me-
dipan Diagnostica, Selchow, Germany);
immunocomplexes were precipitated
with protein A, according to the method
of Schmidli. GADA values 0.9 units/ml
were considered positive. Anti-ICAs were
assayed by indirect immunoﬂuorescence
on frozen sections of pancreata of human
blood group O with ﬂuorescein isothio-
cyanate–conjugated rabbit antibodies.
ICApositivitywasexpressedinJuvenileDi-
abetes Foundation units (JDF-U) by a stan-
dard curve based on the international
JDF-U reference sera sample. An ICA 5
JDF-U was considered positive. Both sensi-
tivity and speciﬁcity were 100% at the 4th
GADA and 13th ICA proﬁciency program
of the Research Institute for Children, New
Orleans, Louisiana (Laboratory no. 13).
Statistical analysis
DataareshownasmeansSD,exceptfor
nonnormally distributed variables (trig-
lycerides and C-peptide), which were an-
alyzed after a logarithmic transformation
and are referred to in tables as geometric
mean (interquartile range). Pearson cor-
relations were performed. Multiple linear
regression analysis was performed to as-
sess variables independently associated
with fasting plasma C-peptide. We then
performed logistic regression analysis in
ordertostudyvariablesindependentlyas-
sociatedwithmicrovascular(retinopathy,
micro- and macroalbuminuria, and dia-
betic neuropathy) and macrovascular
complications (myocardial infarction, an-
gina, coronary artery bypass graft, stroke,
and peripheral arteriopathy). The inde-
pendent role of C-peptide was examined
using tertiles of its distribution (0.06,
0.06–0.10,and0.11–2.76nmol/l).Odds
ratios(ORs)inthesecondandthirdtertile
were similar and were aggregated as the
referencecategoryintheﬁnalanalysisand
compared with the lowest tertile. The
variablesassessedinthemodelswereage,
mean cumulative A1C, gap between mea-
surementofC-peptideandlastclinicalas-
sessment, positivity of markers of -cell
autoimmunity (ICA and GADA), BMI,
micro- and macrovascular complications,
lipids, blood pressure, smoking, and
treatment with ACE inhibitors or sartans.
We compared nested models using both
the backward and forward strategy (20);
two models are nested if both contain the
same predictors and one has at least one
additional predictor. In the ﬁnal analysis,
we included variables that were signiﬁ-
cantly associated with the independent
variable on a likelihood ratio test basis or
that modiﬁed ORs for other variables in-
cluded (20). All analyses were performed
using Stata 10 (StataCorp, College Sta-
tion, TX).
RESULTS— Mean diabetes duration
in the 471 individuals recruited for the
present analyses was 15.8  10.2 years
(range 5.2–39). As shown in Table 1,
characteristics of individuals by C-
peptide tertiles were similar apart from
diabetes duration and plasma triglycer-
ides, which were signiﬁcantly higher in
those in the lowest tertile, and HDL cho-
lesterol values, which were signiﬁcantly
lower in those in the lowest tertile. Resid-
ual -cell secretion was detected even
many years after diabetes diagnosis. In-
deed, almost 50% of people with C-
peptide values in the upper tertile had
Table 1—Characteristics of the clinic-based cohort of 471 individuals with type 1 diabetes by
C-peptide tertile
C-peptide tertile (nmol/l)
P 0.06 0.06–0.10 0.11–2.76
n 201 148 122 —
Male 111 (55.2) 79 (53.4) 75 (61.5) 0.38
Age (years) 38.2  10.5 38.6  9.4 39.1  9.7 0.79
Diabetes duration (years) 13.9 (7.5–19.8) 11.1 (4.9–19.2) 4.0 (0.8–8.5) 0.001
10 38 (23.0) 43 (26.1) 84 (50.9) 0.0001
10–19 79 (48.8) 58 (35.8) 25 (15.4)
20–29 56 (55.4) 34 (33.7) 11 (10.9)
30 28 (65.1) 13 (30.2) 2 (4.7)
BMI (kg/m
2) 24.1  3.4 24.5  3.6 24.5  4.1 0.50
Systolic blood pressure (mmHg) 123.1  15.8 121.9  15.2 120.3  14.9 0.29
Diastolic blood pressure (mmHg) 74.4  9.9 74.4  9.1 75.1  8.9 0.74
Glucose (mmol/l) 12.4  5.8 12.9  5.2 12.1  5.3 0.51
A1C (%) 8.2  1.3 8.2  1.3 8.0  1.4 0.44
Positivity for autoimmunity 119 (65.4) 98 (72.1) 102 (85.7) 0.001
Total cholesterol (mmol/l) 5.20  1.00 5.28  1.05 5.00  1.18 0.10
HDL cholesterol (mmol/l) 1.56  0.47 1.57  0.47 1.41  0.45 0.005
LDL cholesterol (mmol/l) 3.14  0.83 3.18  0.85 2.96  0.96 0.12
Triglycerides (mmol/l) 0.96 1.01 1.11 0.05
Data are means  SD, n (%), or geometric mean (25th–75th percentile) unless otherwise indicated.
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trast, no differences between tertiles were
found in BMI, blood pressure, glycemic
control, or LDL cholesterol. In the whole
cohort, frequency of positivity of markers
of-cellsautoimmunity(ICAandGADA)
was high (73.0%); frequency, however,
was higher in individuals with C-peptide
values in the upper tertile than in those
with values in the lower tertile (85.7 vs.
65.4%).
In univariate analysis, fasting C-
peptide values were positively correlated
with age at diagnosis (r  0.32; P 
0.0001), triglycerides (r  0.14; P 
0.0002), and BMI (r  0.11; P  0.006)
and negatively with diabetes duration
(r  0.34; P  0.0001) and HDL cho-
lesterol (r  0.16; P  0.0001),
whereas no signiﬁcant correlations were
found with age, A1C, blood pressure, or
total or LDL cholesterol. In multivariate
linear regression analysis, fasting plasma
C-peptide values were positively associ-
ated with age at diagnosis (0.02; P 
0.0001) and BMI (0.03; P  0.02)
and inversely associated with duration of
disease ( 0.03; P  0.0001) inde-
pendently of positivity for markers of
-cell autoimmunity (ICA and GADA)
(0.12; P  0.27). After inclusion of
HDL cholesterol ( 0.006; P  0.03)
and triglycerides (0.20; P  0.05),
however,theassociationwithBMIwasno
longersigniﬁcant;indeed,BMIwassignif-
icantly correlated with both HDL choles-
terol (r  0.15; P  0.0001) and
triglycerides (r  0.28; P  0.0001). The
ﬁnal model explained 21% of fasting C-
peptide variability.
Table 2 shows the characteristics of
the cohort by diabetes duration. Age was
higherinindividualswithlongerdiabetes
duration, whereas fasting C-peptide lev-
els were signiﬁcantly lower. Prevalence of
bothmicro-andmacrovascularcomplica-
tions was high, particularly in individuals
with longer diabetes duration: at the ﬁnal
clinical assessment, 90% of the subgroup
with duration 30 years had at least one
microvascular complication and 21.7%
had one macrovascular complication.
We then performed logistic regres-
sion analyses of variables associated with
micro- or macrovascular complications at
the last clinical assessment (Table 3). Re-
garding microvascular complications, we
showed that with respect to C-peptide
valuesinthelowesttertile(0.06nmol/l)
highervaluesconferredaprotectiveeffect
(0.59 [0.37–0.94]). This ﬁnding was in-
dependent of age, sex, diabetes duration,
individual cumulative A1C average dur-
ing the study period, hypertension, and
cardiovascular diseases; all of these vari-
ables correlated with signiﬁcantly in-
creased likelihood of microvascular
complications, as shown by point esti-
matesofORsandlowerlimitsofCIs,both
exceeding 1. Further adjustment for ei-
ther lag time between diabetes C-peptide
evaluationandﬁnalclinicalassessmentor
treatment with ACE-inhibitors/sartans
did not modify observed associations.
With regard to macrovascular com-
plications, no independent associations
with either fasting plasma C-peptide val-
ues (OR 0.77 [CI 95% 0.38–1.58]) or
meancumulativeA1C(0.93[0.57–1.50])
were found, whereas other well-known
risk factors (hypertension, LDL choles-
terol, and microvascular complications)
provided signiﬁcant OR values.
CONCLUSIONS — Results of our
clinic-based study pointed out that 1)
people with type 1 diabetes and higher
fasting C-peptide values had lower prev-
alence of microvascular complications in-
dependently of duration of diabetes,
individual cumulative average of A1C,
and other risk factors, whereas no similar
association was found with macrovascu-
larcomplications;2)residual-cellsecre-
tion was detected even many years after
diabetesdiagnosis;and3)90%ofindivid-
uals with diabetes duration 30 years
had at least one microvascular complica-
tion.
Our study extended previous knowl-
edge (1–3), based on a large cohort of pa-
tients cared for in a single health care
structure, with centralized measurements
of all examined variables and standard-
ized procedures of complications assess-
ment. A study conducted on 97 type 1
diabetic individuals showed that measur-
able C-peptide levels in urine were signif-
icantly associated with lower A1C and
lower prevalence of retinopathy and mi-
croalbuminuria (1). In another study re-
cruiting 160 diabetic individuals, higher
levelsofurinaryC-peptideexcretionwere
associated with lower prevalence of dia-
betic retinopathy (2), whereas contrary
ﬁndings were reported in a study includ-
ing 62 subjects only (3). Our results, al-
though based on an observational study
design, are consistent with results ob-
tained from the Diabetes Control and
ComplicationsTrial,showingthatpreser-
vation of even small residual pancreatic
secretion confers a lower risk for micro-
vascular complications independently of
glycemic control (4). Indeed, among in-
tensively treated patients, the risk of de-
Table 2—Characteristics of the clinic-based cohort of 471 individuals with type 1 diabetes by diabetes duration
Duration of diabetes (years)
P 10 10–19 20–29 30
n 165 162 101 43 —
Male 104 (63.0) 91 (56.2) 52 (51.5) 18 (41.9) 0.05
Age (years) 34.2  9.7 37.3  9.0 41.6  8.4 47.5  6.1 0.001
C-peptide (nmol/l) 0.12 (0.08–0.27) 0.05 (0.02–0.10) 0.04 (0.02–0.10) 0.03 (0.01–0.10) 0.0001
Retinopathy
Background 17 (10.3) 48 (29.6) 45 (44.6) 23 (55.5) 0.0001
Preproliferating 0 (0) 5 (3.1) 5 (5.0) 0 (0)
Proliferating 0 (0) 12 (7.4) 15 (14.9) 7 (16.3)
Diabetic nephropathy 2 (1.2) 12 (7.4) 15 (14.9) 7 (16.3) 0.0001
Autonomic or peripheral neuropathy 25 (15.1) 55 (33.0) 53 (52.5) 32 (74.4) 0.0001
All microvascular complications 37 (22.4) 90 (55.6) 76 (75.3) 39 (90.7) 0.0001
Cardiovascular disease 2 (1.2) 5 (3.1) 16 (15.8) 8 (18.6) 0.0001
Data are means  SD, n (%), or geometric mean (25th–75th percentile) unless otherwise indicated.
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times higher in those with immeasurable
fasting plasma C-peptide than in those
with higher residual pancreatic secretion,
whereas data from conventionally treated
patients did not reach statistical signiﬁ-
cance (4).
Studies conducted over the last
15–20 years have shown that strict glyce-
mic control after diabetes diagnosis can
prevent both micro- and macrovascular
complications, and the concept of meta-
bolic memory has been emphasized (21).
In our study, the protective effect of fast-
ing C-peptide values was independent of
cumulative individual averages of A1C
during the study period, suggesting that
the effect could be directly due to the bi-
ological properties of C-peptide. Indeed,
recent trials have suggested that plasma
C-peptide levels might have a beneﬁcial
effect on both diabetic nephropathy and
neuropathy, but evidence is still quite
limited(16–17).Onamolecularlevel,C-
peptidewouldinteractwithitsownmem-
brane receptor and activate two enzymes





Limitations and strengths of our
study should be taken into account. First,
our results are based on a prevalence co-
hort, so results might have been affected
by survival bias. However, the mortality
rateinthisrelativelyyoungcohortisquite
low, thus ruling out a major effect of sur-
vival bias on our results. Second, the ret-
rospective study design did not allow us
toexaminetheroleofbothC-peptideand
glycemic control after diabetes onset; the
centralized assessment of laboratory data,
however, allowed us to include in the
analyses both retrospective and prospec-
tivedataoveralongperiodoftime.Third,
C-peptidelevelswereobtainedatvariable
times both from time of diagnosis and
from the clinical outcome. Diabetes dura-
tion is associated with both increased
prevalence of complications and lower
fasting C-peptide levels. Our results were
virtually unmodiﬁed in multivariate anal-
yses after further adjustment for diabetes
duration; however, residual confounding
effects on our data cannot be ruled out.
Strengths of the study are the large num-
ber of examined people, the centralized
measurements and standardized proce-
dures employed over time, and the high
level of C-peptide measurements avail-
able in the cohort.
In conclusion, our study, based on a
large cohort of type 1 diabetic people,
identiﬁes the protective effect (41%) of
plasma C-peptide levels 0.06 nmol/l on
microvascular complications, indepen-
dent of diabetes duration, glycemic con-
trol, and other confounders. Prospective
studiesareneededtoconﬁrmthehypoth-
esis that early therapeutic interventions
aimed at preserving even small residual
-cell secretion may modify the natural
development of diabetes.
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